PharVision Advisers’s Information Services Group III Stock Holding History

PharVision Advisers’s Portfolio III Stock Details III Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-11,322	Closed	-$43.5K	–	94
2026 Q1	$43.5K	Buy	+11,322	New	+$55.7K	0.44%	92

Other funds holding III

PCMF

Private Capital Management (Florida) Naples, Florida $1.14B AUM 34.86% 1-Year Est. Return

Cerity Partners New York $82.7B AUM 28.53% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

HIM

Hillsdale Investment Management Toronto, Ontario, Canada $4.39B AUM 72.96% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

CIC

Crawford Investment Counsel Atlanta, Georgia $6B AUM 15.13% 1-Year Est. Return

CAG

Crestwood Advisors Group Boston, Massachusetts $6.74B AUM 30.22% 1-Year Est. Return

PharVision Advisers's III Position: Q2 2026 in Review

PharVision Advisers sold out of Information Services Group (III) in Q2 2026, closing a stake of 11,322 shares — an estimated $43.5K sold.

PharVision Advisers first reported a position in III in Q1 2026 and held it in 1 quarter. The position peaked at $43.5K in Q1 2026. 137 funds tracked by Wall St. Rank hold III as of Q2 2026.

PharVision Advisers reported no remaining Information Services Group position as of Q2 2026 after selling out during the quarter.
PharVision Advisers sold 11,322 Information Services Group shares in Q2 2026, an estimated $43.5K.
PharVision Advisers first reported a position in Information Services Group in Q1 2026 and held it in 1 quarter.
PharVision Advisers's Information Services Group position peaked at $43.5K in Q1 2026.
137 funds tracked by Wall St. Rank held Information Services Group as of Q2 2026.

Based on PharVision Advisers's 13F filing for Q2 2026, filed 11 Aug 2026.